Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Olema Oncology (Nasdaq: OLMA) granted stock options to seven new employees to purchase an aggregate of 254,540 shares of common stock, effective August 3, 2026. The awards were approved by the Compensation Committee under Olema’s 2022 Inducement Plan as inducements to employment in line with Nasdaq Listing Rule 5635(c)(4).

The options have a 10-year term and an exercise price of $11.28 per share, equal to the last reported sale price on August 3, 2026. Vesting occurs over four years: 25% on the first anniversary of the vesting commencement date, with the remaining 75% vesting in 36 equal monthly installments, subject to continued employment.

Market Context

ARVN was up 8.04% in the current peer snapshot. That provides contrasting market context for this gr...

Analysis

ARVN was up 8.04% in the current peer snapshot. That provides contrasting market context for this grant, while recent director net selling remains a sourced risk factor to monitor.

Key Figures

New employees: seven employees Shares covered: 254,540 shares Grant effective date: August 3, 2026 +5 more

8 metrics

New employees seven employees Inducement grants effective August 3, 2026

Shares covered 254,540 shares Aggregate common-stock options granted

Grant effective date August 3, 2026 Date the options became effective

Vesting period four years Option vesting schedule

Initial vesting 25 percent Vests on the first anniversary

Monthly installments 36 equal monthly installments Remaining vesting after the first anniversary

Option term 10-year term Term of the stock options

Exercise price $11.28 per share Equal to the August 3, 2026 Nasdaq last sale price

Historical Context

5 past events · Latest: Jul 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 02	Inducement grants	Neutral	+1.0%	Options granted to eight employees under the inducement plan
Jun 02	Inducement grants	Neutral	-1.7%	Options granted to six employees under the inducement plan
May 26	Clinical collaboration	Positive	-0.9%	Bayer collaboration evaluated OP-3136 with NUBEQA in prostate cancer
May 21	Phase 1 clinical data	Positive	-2.7%	Initial OP-3136 data showed manageable effects and partial responses
May 19	Investor conferences	Neutral	+6.6%	Company announced participation in three healthcare investor conferences

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Repeated inducement-grant notices produced mixed 24-hour reactions: 1.03% on Jul 02 and -1.68% on Jun 02.

Key Terms

inducement plan, nasdaq listing rule 5635(c)(4)

2 terms

inducement plan financial

"granted under the Company's 2022 Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to seven new employees to purchase an aggregate of 254,540 shares of the Company's common stock, effective as of August 3, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $11.28 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on August 3, 2026. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

What inducement stock options did Olema Oncology (OLMA) grant on August 3, 2026?

Olema Oncology granted stock options for an aggregate of 254,540 shares to seven new employees. According to Olema, these options were issued under the 2022 Inducement Plan as material inducements to employment in compliance with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and term of the new Olema Oncology (OLMA) inducement options?

The inducement options have an exercise price of $11.28 per share and a 10-year term. According to Olema, the exercise price equals the last reported sale price of its common stock on Nasdaq on August 3, 2026.

How do the Olema Oncology (OLMA) inducement stock options vest for new employees?

The options vest over four years, with 25% vesting on the first anniversary and 75% monthly thereafter. According to Olema, the remaining shares vest in 36 equal monthly installments, contingent on continuous employment through each vesting date.

Under which plan and Nasdaq rule were Olema Oncology (OLMA) inducement grants made?

The inducement grants were made under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). According to Olema, these awards were approved by the Board’s Compensation Committee as material inducements for new hires.

How many employees received Olema Oncology (OLMA) inducement stock options in August 2026?

Seven new employees received stock option grants as inducement awards effective August 3, 2026. According to Olema, these options cover an aggregate of 254,540 shares of common stock and are subject to standard vesting and continued-employment conditions.

Do the Olema Oncology (OLMA) inducement options depend on continued employment for vesting?

Yes, vesting is contingent on each employee’s continuous employment with Olema on the applicable vesting dates. According to Olema, options vest 25% at year one and the balance in 36 monthly installments over the following three years.